Industry Self-Regulation Group’s Knowledge Of Drug Types Questioned By US Homeopathic Firm
Executive Summary
Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.
You may also be interested in...
Avadim Adamant Its Support For Homeopathic Topical Ad Claims Meets FTC Standards
Avadim Health could get FTC scrutiny after it declines to comply with two findings by an industry self-regulation group to discontinue 26 claims for its Theraworx Relief homeopathic products. It says the analysis “misapplied the well-recognized standards of substantiation” established by FTC.
US Senate Considers State-Level EPR Recycling Programs While Mulling Federal Role
The US Senate Committee on Environment and Public Works discussed state extended producer responsibility programs with stakeholders including S.C. Johnson & Son at a 6 March hearing to consider what the “proper role” of the federal government should be to address the plastic waste crisis. Two recycling bills passed the Senate a week later that could help set the stage.
Fighting Fake Beauty: Brands Must Take Bolder Action To Make Counterfeiters Think Twice
Attorneys presenting at the Personal Care Product Council’s 2024 annual meeting outlined measures beauty companies can take to protect their IP and combat counterfeiting operations. While marketing of sham products is not going to stop, companies can cultivate “a reputation within the counterfeiting community of being one of the brands that genuinely understands how to disrupt counterfeiters.”